TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer
| Autor: | Shang-Lang Huang, Ting-Chang Chang, Nian-Kang Sun, Chuck C.-K. Chao |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Paclitaxel Biochemistry 03 medical and health sciences Transactivation 0302 clinical medicine Cell Line Tumor Ovarian carcinoma Biomarkers Tumor medicine Humans Protein kinase B Ovarian Neoplasms Pharmacology Regulation of gene expression Gene knockdown Dose-Response Relationship Drug Interleukin-6 Chemistry medicine.disease Antineoplastic Agents Phytogenic Gene Expression Regulation Neoplastic Toll-Like Receptor 4 Androgen receptor 030104 developmental biology Drug Resistance Neoplasm Receptors Androgen 030220 oncology & carcinogenesis Cancer research Female Signal transduction Ovarian cancer Interferon Regulatory Factor-1 |
| Zdroj: | Biochemical Pharmacology. 186:114456 |
| ISSN: | 0006-2952 |
| Popis: | Ovarian cancer is poorly treatable due, at least in part, to induced drug resistance to taxol- and cisplatin-based chemotherapy. Recent studies showed that ectopic overexpression of toll-like receptor 4 (TLR4) in ovarian cancer cells leads to upregulation of the androgen receptor (AR) and transactivation of taxol resistance genes, thereby causing chemoresistance. In the present study, we examined the signaling pathways involving TLR4 and interleukin 6 (IL-6) that enhance AR expression. Based on transcriptomic analysis, we show that IL-6 functions as a hub gene among the upregulated genes in taxol-treated TLR4-overexpressing ovarian cancer cells. Both the TLR4 activator taxol and IL-6 can induce AKT phosphorylation, whereas TLR4 knockdown or inhibition of the IL-6 signal transducer GP130 abrogates AKT activation. Furthermore, expression of AR and IL-6 is downregulated in TLR4-knockdown, taxol-resistant cells. In addition, TLR4 knockdown inhibits GP130 and IL-6 receptor alpha (IL6Rα) activities, indicating that TLR4 plays a critical role in IL-6 signaling. On the other hand, nuclear translocation of AR is induced by IL-6 treatment, whereas knockdown of endogenous IL-6 reduces AR and TLR4 expression in taxol-resistant ovarian cancer cells. These results indicate that TLR4 and IL-6 play a crucial role in AR gene regulation and function. We also identify interferon regulatory factor 1 (IRF1) as a downstream target of IL-6 signaling and as a regulator of AR expression. Moreover, analysis of clinical samples indicates that high IL-6 expression correlates with poor progression-free survival in ovarian cancer patients treated with taxol. Overall, our findings indicate that the TLR4/IL-6/IRF1 signaling axis represents a potential therapeutic target to overcome AR-based taxol resistance in ovarian cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect